- Exchange: Berlin
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for Resverlogix Corp (RFS)
| Open: | 2.671 | Day's Range: | 2.654 - 2.831 | Volume: | 0 |
|---|---|---|---|---|---|
| Previous Close: | 2.774 | 52wk Range: | 0.983 - 2.919 | 1-Yr Rtn: | +155.93% |
Key Statistics for RFS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(04/2013) | - |
| Relative P/E vs. DAX | - |
| Earnings Per Share (ttm) | - |
| Est. EPS (04/2013) | - |
| Est. PEG Ratio | - |
| Market Cap (M EUR) | 0.00 |
| Shares Outstanding (M) | 0.00 |
| 30 Day Average Volume | 70 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | - |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/30/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for RFS
Company Profile & Key Executives for RFS
Resverlogix Corp. is a biotechnology company focused on developing therapies for unmet medical needs. The Company concentrates on cardiovascular disease, cancer, and fibrotic conditions.
| Donald J McCaffreyPresident/CEO/Secretary | Aaron Bradley Cann "Brad"Chief Financial Officer |
| Allan GordonSenior VP:Clinical Development | Peter YoungSenior VP:Discovery Research |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
RFS News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page